| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8631764 | Journal of Clinical and Translational Endocrinology: Case Reports | 2018 | 6 Pages |
Abstract
CVD, together with a 14-day regimen of high dose lanreotide, may be an effective treatment option for SDHB-related metastatic PGLs. Therefore, further evaluation of somatostatin analogues, preferably lanreotide, in the treatment of metastatic SDHB-related PGLs is warranted. We believe that ours is the first report detailing the successful use of lanreotide treatment prior to a surgical rescue after systemic treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Isabel Tena, José Luis Ponce, Marcos Tajahuerce, José Luis Vercher-Conejero, Manuel Cifrián, Katherine I. Wolf, Marcela Miret, Maribel del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana PalasÃ,